Can-Fite BioPharma receives IRB approval for a Phase IIa study of Namodenoson to treat pancreatic cancer.
Can-Fite BioPharma received IRB approval for a Phase IIa study to treat pancreatic cancer with Namodenoson. This open-label study aims to assess safety and potential efficacy in patients whose disease has progressed despite first-line treatment. Positive data from previous studies encouraged the initiation of this trial, with one patient showing >7 years overall survival in advanced liver cancer.
June 10, 2024
3 Articles